News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Business
Acorda Therapeutics 2Q Loss Widens on Costs
August 4, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
AP -- Acorda Therapeutics Inc. said Tuesday its second-quarter loss widened on higher expenses as it made plans to launch the multiple sclerosis treatment Fampridine-SR.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Layoffs
Rallybio Downsizes by 40% After Dropping Lead Asset
May 9, 2025
·
2 min read
·
Tristan Manalac
Earnings
Novavax Sales Jump 600% YoY as COVID-19 Vaccine Still in Limbo at FDA
May 8, 2025
·
3 min read
·
Heather McKenzie
Cell therapy
Vor Bio Looks for Exit in Challenging Funding Environment; Lays Off 95% of Staff
May 8, 2025
·
1 min read
·
Dan Samorodnitsky
Job Trends
Job Market Woes: More Funding, Stability Needed for Turnaround
May 8, 2025
·
5 min read
·
Angela Gabriel
